ChenGuang Biotech Group Co., Ltd. (SHE:300138)
China · Delayed Price · Currency is CNY 13.54
-0.26 (-1.88%)
At close: Feb 13, 2026
ChenGuang Biotech Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 |
Net Income | 335.27 | 94.05 | 479.72 | 434.03 | 351.51 | 267.74 |
Depreciation & Amortization | 166.5 | 166.5 | 152.83 | 144.85 | 130.74 | 112.29 |
Other Amortization | 0.65 | 0.65 | 0.2 | 0.9 | 0.2 | 0.2 |
Loss (Gain) From Sale of Assets | -4.89 | -4.89 | 0.63 | -1.08 | -0.1 | 0.08 |
Asset Writedown & Restructuring Costs | 0.46 | 0.46 | 1.1 | 1.32 | 10.91 | 9.15 |
Loss (Gain) From Sale of Investments | -12.68 | -12.68 | -74.02 | -33.45 | -30.93 | -11.93 |
Provision & Write-off of Bad Debts | 0.11 | 0.11 | 0.87 | 0.77 | -1.93 | 0.09 |
Other Operating Activities | 689.34 | 197.19 | 80.74 | 100.25 | 74.9 | 91.16 |
Change in Accounts Receivable | 62.07 | 62.07 | 135.24 | -274.17 | -119.09 | 59.4 |
Change in Inventory | -670.57 | -670.57 | -1,145 | 187.13 | -435.93 | 108.08 |
Change in Accounts Payable | -41.67 | -41.67 | -211.8 | 176.31 | 90 | -110.5 |
Operating Cash Flow | 510.56 | -222.81 | -588.47 | 734.81 | 63.9 | 529.41 |
Operating Cash Flow Growth | 2576.05% | - | - | 1049.93% | -87.93% | - |
Capital Expenditures | -93.04 | -149.54 | -189.2 | -176.03 | -280.82 | -436.88 |
Sale of Property, Plant & Equipment | 4.4 | 0.02 | 0.28 | 0.42 | 3.58 | 1.04 |
Investment in Securities | -919.08 | -315.58 | -336.91 | -540.91 | - | -10.06 |
Other Investing Activities | 65.47 | 24.15 | 77.56 | 20.12 | 12.47 | 3.75 |
Investing Cash Flow | -942.25 | -440.95 | -448.27 | -696.4 | -264.76 | -442.14 |
Long-Term Debt Issued | - | 5,783 | 4,678 | 3,511 | 2,081 | 2,573 |
Total Debt Issued | 4,125 | 5,783 | 4,678 | 3,511 | 2,081 | 2,573 |
Long-Term Debt Repaid | - | -5,088 | -3,381 | -3,132 | -1,278 | -2,505 |
Total Debt Repaid | -4,323 | -5,088 | -3,381 | -3,132 | -1,278 | -2,505 |
Net Debt Issued (Repaid) | -198.13 | 695.8 | 1,297 | 378.58 | 803.12 | 68.04 |
Repurchase of Common Stock | -396.53 | -396.53 | -95.84 | - | - | -91.89 |
Common Dividends Paid | -161.2 | -174.05 | -181.41 | -143.98 | -109.77 | -93.87 |
Other Financing Activities | 202.2 | -21.41 | 276.95 | -195.55 | -152.39 | 360.38 |
Financing Cash Flow | -553.66 | 103.8 | 1,297 | 39.05 | 540.96 | 242.66 |
Foreign Exchange Rate Adjustments | -8.76 | -10.49 | -6.05 | -4.94 | -4.36 | -3.91 |
Net Cash Flow | -994.11 | -570.46 | 254.03 | 72.51 | 335.75 | 326.02 |
Free Cash Flow | 417.51 | -372.35 | -777.67 | 558.78 | -216.92 | 92.54 |
Free Cash Flow Margin | 6.13% | -5.32% | -11.32% | 8.88% | -4.45% | 2.37% |
Free Cash Flow Per Share | 0.86 | -0.72 | -1.46 | 1.05 | -0.41 | 0.18 |
Cash Income Tax Paid | - | 7.26 | 9.45 | -46.55 | -31.36 | -20.06 |
Levered Free Cash Flow | -295.15 | 39.79 | -997.32 | -131.42 | -423.74 | -208.18 |
Unlevered Free Cash Flow | -232.26 | 111.3 | -945.13 | -89.42 | -390.52 | -159.39 |
Change in Working Capital | -664.21 | -664.21 | -1,231 | 87.21 | -471.4 | 60.63 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.